Assessment of Patient Use of a New Device: RebiSmart
Launched by MERCK KGAA, DARMSTADT, GERMANY · Sep 3, 2010
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have relapsing remitting multiple sclerosis
- • Between 18 to 65 years old inclusive
- • Have been prescribed Rebif for the first time but not yet started treatment
- • Rebismart as chosen device
- • Be under review by MS nurse
- • Having given written informed consent to participate in the study
- Exclusion Criteria:
- • Injections of Rebif given by someone other than the patient
- • Patients unable to use the Rebismart device due to visual or physical impairment
- • Patients unwilling to give informed consent
- • Contra-indications to Rebif as defined in the Summary of Product Characteristics (SPC).
- • Allergy to the antipyretic analgesics that will be advised as prophylaxis for flu-like symptoms
About Merck Kgaa, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading global science and technology company, specializing in healthcare, life sciences, and performance materials. With a rich history dating back to 1668, Merck KGaA is committed to advancing innovative solutions that improve the quality of life for patients and drive scientific discovery. The company invests significantly in research and development to bring cutting-edge therapies to market, focusing on areas such as oncology, immunology, and neurology. As a dedicated clinical trial sponsor, Merck KGaA collaborates with healthcare professionals and institutions worldwide to conduct rigorous trials that ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and foster global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dr Gillian L Shepherd, MD, MRCP
Study Director
Merck Serono Limited, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials